Analytical Data
-
基因名
CACNa1E
- Application
-
别名
CACNa1E；EF-hand domain-containing Protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q15878
-
表达区间
全长
-
氨基酸序列
full
-
分子量
261 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CACNa1E, a member of the voltage-gated calcium channel family, plays a crucial role in the regulation of calcium ion influx across the plasma membrane, which is essential for various physiological processes, including neurotransmitter release, muscle contraction, and gene expression. Research on CACNa1E has gained significant attention due to its implications in neurological disorders, cardiovascular diseases, and other health issues. The reconstitution and characterization of CACNa1E recombinant protein have become pivotal for understanding its structure-function relationships and pharmacological properties. By studying this protein, researchers aim to elucidate the molecular mechanisms underlying its activity and to identify potential therapeutic targets for diseases associated with calcium channel dysfunction. Advances in molecular biology techniques, such as recombinant DNA technology and expression systems, have facilitated the production of high-purity CACNa1E proteins, allowing for detailed functional assays and structural analyses. These studies are vital not only for enhancing our understanding of calcium channels in health and disease but also for developing innovative strategies for drug discovery aimed at modulating CACNa1E activity.
